Icon downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded Icon (ICLR) to Neutral from Buy with a price target of $200, down from $250. While the firm continues to believe that the company is one of the leaders in the clinical Contract Research Organization space, it is now less positive on the near term outlook for Icon as a pure play CRO following less consistent performance in recent quarters, combined with a weaker than expected demand environment, the analyst tells investors.